Scientists at the University of Cambridge have announced the creation of a vaccine whose primary component was designed entirely by artificial intelligence and subsequently tested in human subjects. The research team engineered the vaccine to provide protection against all coronaviruses, encompassing existing Covid variants and animal viruses with potential pandemic risk. The work remains preliminary, though researchers are concurrently developing additional vaccines targeting influenza and Ebola.
Vaccines function by training the immune system to recognize infections and mount defensive responses. However, viruses that readily mutate—such as Covid and seasonal flu—can render vaccines ineffective over time. The Cambridge team approached vaccine design differently by analyzing genetic sequences from multiple coronaviruses collected through surveillance programs. Artificial intelligence then processed this data to create a “super-antigen” capable of training immune systems to recognize and combat an entire viral family, even accounting for mutations or novel animal-to-human transmission events.
The initial human trial involved 39 participants and focused on safety assessment. A subsequent study with approximately 200 participants will examine immune system activation more thoroughly. According to findings published in the Journal of Infection, the immune response was characterized as “modest” yet generated considerable interest within the scientific community. Prof Saul Faust, who conducted some trials, noted that the AI approach shows distinct advantages in designing vaccines for emerging pandemic threats amid rapidly evolving viruses.
The Cambridge research team is pursuing additional applications, including universal seasonal flu vaccines requiring no annual reformulation and protection against H5N1 bird flu. They are also investigating vaccines for viral haemorrhagic fevers, including Ebola variants currently lacking approved vaccines. Independent experts characterized the findings as compelling, though they emphasized that human immune systems differ substantially from laboratory models due to accumulated exposure to infections. Observers broadly assessed artificial intelligence as transformative for vaccine development, with potential to accelerate development timelines and improve outcomes.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI